Predictive partners with Tecan Group for high-throughput drug screening

Predictive Oncology (POAI) announced that positive results from an ongoing study in collaboration with Switzerland-based Tecan, Ltd. were recently presented at the 2025 Society for Laboratory Automation and Screening International Conference & Exhibition, which was held January 25-29, 2025, in San Diego, CA. Optimized growth conditions and drug treatment protocols were established for tumor models derived from cryopreserved DTCs of different cancer types. 3D models are closer to in vivo physiological conditions than 2D models, and as expected, differences in response to drug dosing are observed.